[Featured Stock] InventiLab Discusses Joint Development of Obesity Treatment with Big Pharma... "Focus on Long-Acting Injectable"

Inventage Lab is showing strong performance. It appears that securities firms' analysis, which suggests that the company is discussing joint development of obesity treatments with big pharma, has had an impact.

As of 9:30 AM on the 3rd, Inventage Lab was trading at 18,030 KRW, up 2,760 KRW (18.07%) compared to the previous trading day.

Inventage Lab is a company developing long-acting injectable (LAI) drugs. Jeonghyun Kim, a researcher at Kyobo Securities, explained, "With the explosive growth of the obesity treatment market recently, LAI technology is being re-evaluated. Both early and late entrants are considering formulation differentiation strategies for their follow-up pipelines, and market participants are very interested in the possibility of launching oral or long-acting formulations."

He added, "To develop obesity treatments as LAI, it is necessary to prove an ideal drug release pattern and tolerability, and big pharma is actively seeking related technologies."

In particular, Researcher Kim emphasized that if considering investment in domestic obesity treatments, significant attention should be paid to Inventage Lab. He stated, "It is known that discussions on joint development of obesity treatment LAI with other big pharma companies have also begun," and "business achievements are expected in the near future." He continued, "If they can provide technology that addresses the unmet needs of the obesity treatment market, they will attract great interest from investors."